Cochrane for Clinicians
Putting Evidence into Practice
DPP-4 Inhibitors and GLP-1 Receptor Agonists for Prevention or Delay of Type 2 Diabetes Mellitus and Associated Complications
Am Fam Physician. 2018 Apr 1;97(7):437-438.
Author disclosure: No relevant financial affiliations.
Are dipeptidyl-peptidase-4 (DPP-4) inhibitors or glucagon-like peptide-1 (GLP-1) receptor agonists effective in preventing type 2 diabetes mellitus and its associated complications in patients at increased risk?
There is only limited-quality evidence that at-risk patients taking GLP-1 receptor agonists are less likely to progress to diabetes (number needed to treat [NNT] = 23). Serious adverse events were more likely in patients taking GLP-1 receptor agonists than in patients taking placebo (number needed to harm [NNH] = 42). There is insufficient evidence to evaluate the effect of DPP-4 inhibitors on at-risk patients. There is no evidence that either medication class affects the development of diabetes-associated complications.1 (Strength of Recommendation: C, based on low-quality, disease-oriented evidence.)
In the United States alone, an estimated 30.3 million persons have diabetes and 84.1 million have prediabetes,2 and 70% to 90% of those with prediabetes progress to diabetes.3 Microvascular and macrovascular complications of diabetes begin to occur while patients are still in the prediabetic stage.3,4 Metformin and acarbose (Precose) have been shown to decrease the risk of some of these complications, but data for other medications are lacking.5,6
This Cochrane review included seven randomized controlled trials.1 Because of the limited number of participants—only 98 patients—and the lack of patient-oriented outcomes data from the two DPP-4 inhibitor trials, no conclusions could be drawn about that class of medication. The remaining five trials included 1,620 participants randomized to monotherapy with a GLP-1 receptor agonist.
In a single randomized, double-blind, placebo-controlled trial, authors studied the effect of liraglutide (Victoza; a GLP-1 receptor agonist) in patients with prediabetes and obesity. After 160 weeks, fewer patients treated with liraglutide developed diabetes than those treated with placebo (1.8% vs. 6.2%; absolute risk reduction = 4.3%; NNT = 23). Because of limited data, no conclusions could be drawn regarding the effect of GLP-1 receptor agonists to decrease the risk of complications associated with diabetes.
Patients receiving GLP-1 receptor agonists may experience serious adverse events including, but not limited to, myocardial infarction, cholelithiasis, cholecystitis, pancreatitis, intervertebral disk protrusion, abdominal and hiatal hernia, infection, and neoplasm.7 More individuals who received liraglutide had serious adverse events than those who received placebo (15.1% vs. 12.7%; absolute risk increase = 2.4%; NNH = 42). It is noteworthy that most of the data on GLP-1 receptor agonists came from the same large industry-sponsored study. Because of the small number of participants in the other GLP-1 receptor agonist studies, no comparisons among the different agents and thus no conclusions regarding their relative benefit could be made.
Current guidelines for treating patients with prediabetes advocate lifestyle modification, optimizing comorbid conditions, and—in high-risk individuals—metformin to decrease progression to diabetes.5,6 The American Diabetes Association acknowledges that other medications, including acarbose, orlistat (Xenical), GLP-1 receptor agonists, and thiazolidinediones, can decrease the incidence of progression to diabetes, but recommends metformin based on the strong evidence and long-term safety data.5
The practice recommendations in this activity are available at http://www.cochrane.org/CD012204.
The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, the Department of Defense, or the U.S. government.
Editor's Note: The number needed to treat, number needed to harm, absolute risk reduction, and absolute risk increase reported in this Cochrane for Clinicians were calculated by the authors based on raw data provided in the original Cochrane review.
Referencesshow all references
1. Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev. 2017;(5):CD012204....
2. Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2017. Atlanta, Ga.: Centers for Disease Control and Prevention, U.S. Department of Health and Human Services; 2017. https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf. Accessed February 27, 2018.
3. Garber AJ, Handelsman Y, Einhorn D, et al. Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. Endocr Pract. 2008;14(7):933–946.
4. Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M. Prediabetes: a high-risk state for diabetes development. Lancet. 2012;379(9833):2279–2290.
5. American Diabetes Association. Prevention or delay of type 2 diabetes: standards of medical care in diabetes–2018. Diabetes Care. 2018;41(suppl 1):S51–S54.
6. Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm. 2018 Executive summary. Endocr Pract. 2018;24(1):91–120.
7. Effect of liraglutide on body weight in non-diabetic obese subjects or overweight subjects with co-morbidities: SCALE™—obesity and pre-diabetes. Updated June 2017. https://clinicaltrials.gov/ct2/show/study/NCT01272219. Accessed September 1, 2017.
These are summaries of reviews from the Cochrane Library.
This series is coordinated by Corey D. Fogleman, MD, Assistant Medical Editor.
A collection of Cochrane for Clinicians published in AFP is available at https://www.aafp.org/afp/cochrane.
Copyright © 2018 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact email@example.com for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions
More in AFP
MOST RECENT ISSUE
May 15, 2021
Access the latest issue of American Family Physician